26 11月 2024 by admin in UncategorizedComments Oricell Therapeutics Receives China NMPA IND Clearance for MSLN/Claudin 18.2 Dual CAR-T Therapy for Solid Tumors
26 11月 2024 by admin in UncategorizedComments Adcentrx Therapeutics Announces FDA Clearance of Investigational New Drug Application for ADRX-0405, a Potential First-in-Class ADC Targeting STEAP1 for the Treatment of Advanced Solid Tumors
20 11月 2024 by admin in UncategorizedComments Avenzo Therapeutics Announces Appointment of Patrick Machado, J.D. to Board of Directors as Independent Director
19 11月 2024 by admin in UncategorizedComments Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
18 11月 2024 by admin in UncategorizedComments Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
12 11月 2024 by admin in UncategorizedComments Zenas BioPharma Completes Targeted Enrolment of the Phase 3 INDIGO Trial of Obexelimab in Imunoglobulin G4-Related Disease (IgG4-RD) in Immunoglobulin G4-Related Disease (IgG4-RD)
12 11月 2024 by admin in UncategorizedComments Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
10 11月 2024 by admin in UncategorizedComments Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
23 10月 2024 by admin in UncategorizedComments Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies
16 10月 2024 by admin in UncategorizedComments Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome
